logo-loader
RNS
viewAdvanced Oncotherapy PLC

Advanced Oncotherapy - Holding(s) in Company

RNS Number : 1610Q
Advanced Oncotherapy PLC
17 June 2020
 

17 June 2020

 

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

 

Holding(s) in Company

 

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, has been informed that Mr Seamus Mulligan has a total beneficial interest in 30,405,721 ordinary shares of 25p each in the Company ("Ordinary Shares"), representing 9.92% of the Company's issued share capital. Mr Mulligan's interest is held as to 22,500,000 Ordinary Shares by Nerano Capital Limited (a 100% subsidiary of Nerano Pharma Limited) and 7,905,721 Ordinary Shares by Barrymore Investments Limited.

 

Advanced Oncotherapy plc

www.avoplc.com

Dr. Michael Sinclair, Executive Chairman

Tel: +44 (0) 20 3617 8728

Nicolas Serandour, CEO

 

 




Allenby Capital Limited (Nomad & Broker)


Nick Athanas / Liz Kirchner / Nicholas Chambers

 

 

Tel: +44 (0) 20 3328 5656



FTI Consulting (Financial PR & IR)

[email protected]

Simon Conway / Rob Winder

Tel: +44 (0) 20 3727 1000

 

 

Notes for Editors

 

About Advanced Oncotherapy Plc www.avoplc.com

 

Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.

 

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.

 

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
HOLUNAWRRBUNAAR

Quick facts: Advanced Oncotherapy PLC

Price: 25.5

Market: LSE
Market Cap: £78.12 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Advanced Oncotherapy One2One Investor Presentation 29th October 2013-DUBLIN

Advanced Oncotherapy One2One Investor Presentation 29th October 2013-DUBLIN

on 10/29/2013